A randomized phase III trial of postoperative adjuvant oral fluoropyrimidine vs. sequential paclitaxel / oral fluoropyrimidine; and UFT vs. S1 for T3 / T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (SAMIT) Trial.
Phase of Trial: Phase III
Latest Information Update: 12 May 2016
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary) ; Tegafur/uracil (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SAMIT
- 04 Jun 2013 Primary endpoint 'Disease-free-survival' has not been met.
- 04 Jun 2013 Status changed from active, no longer recruiting to completed.
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.